Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Post by Thetrading999on Jun 08, 2018 8:20am
115 Views
Post# 28144600

NR on Patents

NR on Patents

 

ORIGINAL: Clarification and Retraction of Previously Announced Press Release: Lifestyle Delivery Systems Inc. Announces Update on Trademarks and Patent Issues

 

2018-06-08 08:00 ET - News Release

 

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2018) - Lifestyle Delivery Systems Inc. (CSE: LDS) (FSE: LD6) (OTCQX: LDSYF) ("LDS" or the "Company") NOTIFIES its readers that the Company retracts the news release the Company issued on April 18, 2018, entitled Lifestyle Delivery Systems Inc. announces Update on Trade Marks and Patent (the "Original Press Release"). The following Revised Press Release replaces the Original Press Release and provides additional information and clarification on certain statements regarding CTT Pharmaceutical Holdings, Inc.'s ("CTT Pharmaceutical") Canadian Patent No. 2,922,959 ("the '959 patent").

Vancouver, British Columbia, Canada, June 8, 2018, Lifestyle Delivery Systems Inc. (CSE: LDS) (FSE: LD6) (OTCQX: LDSYF) announces updates on trademark filings and scheduling of clinical trials for bio-availability of its CannaStripsTM technology.

The CannaStripsTM logo and tagline "Smoke Free Pain Relief" have been issued European Union trade mark registration numbers 017383712 and 017383738 by the European Union Intellectual Property Office and the United Kingdom trade mark registration numbers UK00003265774 and UK00003265768, issued by the United Kingdom Intellectual Property Office. The Company has also applied for trademark protection in California. These marks are in addition to the Canadian trademark applications the Company has filed with the Canadian Intellectual Property Office on April 25, 2017.

The Company is scheduling clinical trials to commence in June 2018 to define the bio-availability benefits of the Lifestyle Delivery Systems' CannaStripsTM technology. These clinical trials are expected to quantify the enhanced delivery method of CannaStripsTM compared to other forms of delivery.

On February 21, 2018, CTT Pharmaceutical announced issuance of its Canadian Patent No. 2,922,959. The Company does not believe the CannaStripsTM product infringes any claims of CTT Pharmaceutical's patent and believes the patents will not restrict the Company's ability to operate in Canada or the United States. In addition, over twenty years ago, United States Patent No. 6,017,545 ("the '545 patent") was filed. The inventor on the face of the '545 patent is the CEO of CTT Pharmaceutical, Pankaj Modi, and the subject matter of the '545 patent overlaps with the '959 patent. There is no public assignment record of the '545 patent from Dr. Modi to CTT Pharmaceutical. The '545 patent expired on February 10, 2018, and the Company's development of the CannaStripsTM technology did not infringe the '545 patent. The Company is not currently aware of any CTT patents that it believes will limit its ability to bring the CannaStripsTMtechnology to market.

About Lifestyle Delivery Systems Inc.

Lifestyle Delivery Systems Inc. is a licensed, state-compliant vertically integrated cannabis-related company. From our isogenic pollination nursery to our cutting edge, state-of-the-art production facility located in Southern California, LDS has become one of the most diverse, innovative and scientifically based cannabis companies throughout North America. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking but also a new way to accurately meter the dosage and assure the purity of the product. From start to finish, the production process tests for quality and composition of all the ingredients used in each and every strip, resulting in a delivery system that is safe, consistent and effective.

On behalf of the board of directors of Lifestyle Delivery Systems Inc.

Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
investor.relations@lifestyledeliverysystem.com
1-866-347-5058

Cautionary Disclaimer Statement:

 

 

ORIGINAL: Clarification and Retraction of Previously Announced Press Release: Lifestyle Delivery Systems Inc. Announces Update on Trademarks and Patent Issues

 

2018-06-08 08:00 ET - News Release

 

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2018) - Lifestyle Delivery Systems Inc. (CSE: LDS) (FSE: LD6) (OTCQX: LDSYF) ("LDS" or the "Company") NOTIFIES its readers that the Company retracts the news release the Company issued on April 18, 2018, entitled Lifestyle Delivery Systems Inc. announces Update on Trade Marks and Patent (the "Original Press Release"). The following Revised Press Release replaces the Original Press Release and provides additional information and clarification on certain statements regarding CTT Pharmaceutical Holdings, Inc.'s ("CTT Pharmaceutical") Canadian Patent No. 2,922,959 ("the '959 patent").

Vancouver, British Columbia, Canada, June 8, 2018, Lifestyle Delivery Systems Inc. (CSE: LDS) (FSE: LD6) (OTCQX: LDSYF) announces updates on trademark filings and scheduling of clinical trials for bio-availability of its CannaStripsTM technology.

The CannaStripsTM logo and tagline "Smoke Free Pain Relief" have been issued European Union trade mark registration numbers 017383712 and 017383738 by the European Union Intellectual Property Office and the United Kingdom trade mark registration numbers UK00003265774 and UK00003265768, issued by the United Kingdom Intellectual Property Office. The Company has also applied for trademark protection in California. These marks are in addition to the Canadian trademark applications the Company has filed with the Canadian Intellectual Property Office on April 25, 2017.

The Company is scheduling clinical trials to commence in June 2018 to define the bio-availability benefits of the Lifestyle Delivery Systems' CannaStripsTM technology. These clinical trials are expected to quantify the enhanced delivery method of CannaStripsTM compared to other forms of delivery.

On February 21, 2018, CTT Pharmaceutical announced issuance of its Canadian Patent No. 2,922,959. The Company does not believe the CannaStripsTM product infringes any claims of CTT Pharmaceutical's patent and believes the patents will not restrict the Company's ability to operate in Canada or the United States. In addition, over twenty years ago, United States Patent No. 6,017,545 ("the '545 patent") was filed. The inventor on the face of the '545 patent is the CEO of CTT Pharmaceutical, Pankaj Modi, and the subject matter of the '545 patent overlaps with the '959 patent. There is no public assignment record of the '545 patent from Dr. Modi to CTT Pharmaceutical. The '545 patent expired on February 10, 2018, and the Company's development of the CannaStripsTM technology did not infringe the '545 patent. The Company is not currently aware of any CTT patents that it believes will limit its ability to bring the CannaStripsTMtechnology to market.

About Lifestyle Delivery Systems Inc.

Lifestyle Delivery Systems Inc. is a licensed, state-compliant vertically integrated cannabis-related company. From our isogenic pollination nursery to our cutting edge, state-of-the-art production facility located in Southern California, LDS has become one of the most diverse, innovative and scientifically based cannabis companies throughout North America. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking but also a new way to accurately meter the dosage and assure the purity of the product. From start to finish, the production process tests for quality and composition of all the ingredients used in each and every strip, resulting in a delivery system that is safe, consistent and effective.

On behalf of the board of directors of Lifestyle Delivery Systems Inc.

Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
investor.relations@lifestyledeliverysystem.com
1-866-347-5058

Cautionary Disclaimer Statement:

 

Bullboard Posts